Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05526807
  4. Details
NCT05526807 Clinical Trial

Ursodeoxycholic Acid in C. Difficile Infection

Clostridioides Difficile Infection Clinical Trial

Official title:
Feasibility Studies to Investigate the Role of Ursodeoxycholic Acid in the Prevention of Recurrence of C. Difficile Infection

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT05526807
Other study ID # 17GA025
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 8, 2019
Est. completion date December 31, 2023

Study information
Verified date April 2024
Source Nottingham University Hospitals NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid

Recruitment information / eligibility
Status Terminated
Enrollment 6
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Completion of a course of antibiotic treatment for C. difficile infection within the previous 7 days Exclusion Criteria: - • Pregnant or Breast-feeding - Gall bladder inflammation - Frequent episodes of biliary colic - Occlusion of the common bile duct or cystic duct - Active small intestinal inflammation - Previous resection of distal small intestine - Treatment with bile salt binding agents, ciclosporin or ciprofloxacin - Diarrhoea (from any cause) at study initiation - hypersensitivity to bile acids or any excipient of the formulation - Life expectancy less than 6 months

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Ursodeoxycholic acid
Oral

Locations
Country Name City State
United Kingdom Nottingham University Hospitals NHS Trust Nottingham

Sponsors (1)
Lead Sponsor Collaborator
Nottingham University Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary To assess tolerability to oral ursodeoxycholic acid Assess for side effects 6 weeks
Secondary To determine recurrence of C. difficile infection in those able to take ursodeoxycholic acid Recurrence of C. difficile infection to be confirmed by stool test for toxin(s) 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03895593 - Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
Withdrawn NCT04679324 - The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
Completed NCT04675723 - The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
Recruiting NCT05693077 - Clostridioides Difficile Colonisation Phase 1
Completed NCT04668014 - The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection
Completed NCT03183141 - ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection Phase 3
Recruiting NCT05709184 - Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection N/A
Terminated NCT04802837 - Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects Phase 3
Active, not recruiting NCT04885946 - Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection N/A
Recruiting NCT04305769 - Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) Phase 2
Recruiting NCT06106698 - Washed Microbiota Transplantation for Clostridioides Difficile Infection
Active, not recruiting NCT04781387 - Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection Phase 2
Completed NCT03595566 - To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Phase 3
Completed NCT03595553 - Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Phase 3
Completed NCT04725123 - Addressing Personalized Needs in Clostridioides Difficile Infection N/A
Not yet recruiting NCT05852587 - Xylitol Use for Decolonization of C. Difficile in Patients With IBD Phase 1
Completed NCT03788434 - Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 2
Recruiting NCT05612672 - Evaluation of GeoHAI Implementation N/A
Recruiting NCT05320068 - Oral Vancomycin vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection Phase 3
Not yet recruiting NCT05330182 - LMN-201 for Prevention of C. Difficile Infection Recurrence Phase 2/Phase 3